EP Patent

EP2086570A1 — Use of beta-lactamase

Assigned to Ipsat Therapies Oy · Expires 2009-08-12 · 17y expired

What this patent protects

Class A beta-lactamase may be used for reducing side- effects in the intestine associated with antibiotic therapy with a combination of beta-iactam antibiotic and beta- lactamase inhibitor.

USPTO Abstract

Class A beta-lactamase may be used for reducing side- effects in the intestine associated with antibiotic therapy with a combination of beta-iactam antibiotic and beta- lactamase inhibitor.

Drugs covered by this patent

Patent Metadata

Patent number: EP2086570A1
Jurisdiction: EP
Classification: —
Expires: 2009-08-12
Drug substance claim: No
Drug product claim: No
Assignee: Ipsat Therapies Oy
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.